PERSISTENCE OF SIGNS AND SYMPTOMS IN TREATED PATIENTS WITH IGAN: EVIDENCE FROM REAL-WORLD DATA
Back
Abstract Number
WCN23-0383
Categories
Chronic Kidney Disease, Hypertension, Diabetes and CVD
Topic - Chronic Kidney Disease, Hypertension, Diabetes and CVD
Nephrotic Syndrome
Topic - AKI, Electrolytes, Acid-base Disorders, Tropical Diseases, RPGN and Pregnancy
Topic - Kidney Failure (Former ESKD), incl. Dialysis, Transplantation, Conservative Care
Topic - Special Covid-19
Topic - Education
Abstract Title
PERSISTENCE OF SIGNS AND SYMPTOMS IN TREATED PATIENTS WITH IGAN: EVIDENCE FROM REAL-WORLD DATA
Co-authors
Lafayette, R.(1)*;Kroes, M.(2);Aldworth, C.(3);Rodriguez, L.P.(4);George, A.T.(5);Wang, W.(3);De Courcy, J.(6);Golden, K.(6);Chatterton, E.(6);Yao, L.(7);Roccatello, D.(8);
ie:
Azwin Z.1, Siti Y.1, John D.2
Institution
(1)Stanford University Of Medicine, Nephrology, Stanford, United States;(2)Novartis Pharma Ag, Global Heor, Basel, Switzerland;(3)Novartis Pharmaceuticals Corporation, Medical, New Jersey, United States;(4)Novartis Pharma Ag, Global Medical Affairs, Basel, Switzerland;(5)Novartis Healthcare Pvt. Ltd., Value And Access, Hyderabad, India;(6)Adelphi Real World, Real World, England, United Kingdom;(7)The First Hospital Of China Medical University, Nephrology, Shenyang, China;(8)University Of Turin, Nephrology, Turin, Italy;
E-Poster
https://storage.unitedwebnetwork.com/files/1041/7c5babee7ad03c0de5eeff2ad1b4951d.pdf
Audio File
if any